Metraipolis › archive › dc_7d358a1cd40a
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with… — Europe PMC PMID:41079427
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41079427
- DOI
- 10.1177/17562848251383767
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T12:39:12.626Z
- SHA-256 of the archived text
6dc00e91a75ea84520704c571dc8c1d86aa7daede74bf04f2a6bdb9978f7f49e- Stable URL of this page
https://metraipolis.com/documento/dc_7d358a1cd40a
How to cite
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with… — Europe PMC PMID:41079427 — Europe PMC (en), https://europepmc.org/article/MED/41079427 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7d358a1cd40a (Metraipolis archive dc_7d358a1cd40a, sha256 6dc00e91a75ea84520704c571dc8c1d86aa7daede74bf04f2a6bdb9978f7f49e)
BibTeX
@misc{dc7d358a1cd40a,
title = {Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with… — Europe PMC PMID:41079427},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41079427},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7d358a1cd40a; sha256 6dc00e91a75ea84520704c571dc8c1d86aa7daede74bf04f2a6bdb9978f7f49e},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41079427. Agents can read the archived copy with the MCP tool read_document.